ITGB2 and cancer: It has been demonstrated that cancer, and all the therapies associated with this illness, promote functional alterations in monocytes, such as the acquisition of immunosuppressive activity in the tumor microenvironment, which is related to the expression of CD11b an integrin that, when binds to CD18 promotes the acceleration of the invasiveness and metastasis of cancer cells [26].